Navigation Links
New technology aims to reduce maternal and neonatal deaths
Date:12/18/2008

London, ON A new technology that could help physicians screen pregnant women at risk of developing a prenatal and potentially fatal complication called preeclampsia has been developed at The University of Western Ontario and the Children's Health Research Institute of Lawson Health Research Institute.

The technology, employing a panel of biomarkers found to have changed levels in the placenta of women who develop preeclampsia, has been licensed to California-based Biosite Inc. for further development and eventual commercialization.

As one of the leading causes of maternal and neonatal deaths worldwide, preeclampsia does not discriminate socioeconomic status or geography, and affects approximately 3-10 per cent of all pregnancies. According to the World Health Organization, it is responsible for 18 per cent of all maternal deaths, 80,000 premature births and associated neonatal complications, which can have life-long impact such as cerebral palsy, mental retardation and blindness.

Screening and early detection are key given that there are no known cures for preeclampsia, and the only treatment available to date is to deliver the baby and placenta at any stage of gestation at which the disease is diagnosed. The work has been supported by grants from the Canadian Institutes of Health Research, Western and the Children's Health Foundation.

"Our research is highly relevant to early-onset severe preeclampsia that presents before 28 weeks gestation," says Dr. Victor Han, Canada Research Chair in Fetal and Maternal Health, at the Schulich School of Medicine & Dentistry at Western, and one of the team's lead researchers. "By identifying these pregnant women early, one day, we will be able to delay the onset or reduce the severity by targeted intervention."

Han, biochemistry professor Gilles Lajoie and recent Master's graduate Aaron Booy set out to identify an 'early warning system' for preeclampsia and have developed a patent-pending method for identifying proteins and related biomarkers that, in combination, will predict the likelihood of and risk associated with the disease. This important discovery could lead to the development of diagnostic tests used by physicians to identify at-risk pregnancies more quickly and more effectively.

This finding drew the immediate attention of Biosite Inc., a division of Inverness Medical Innovations, which is a world leader in the area of medical diagnostics. Biosite Inc. will help support the researchers' continued efforts by developing reagents and immunoassays to enable the biomarkers to be measured in patients' blood specimens and take the technology to market.

The deal is one of the first completed by London's new WORLDiscoveries business development office, which is a partnership between Western, including Robarts Research Institute, and Lawson Health Research Institute.


'/>"/>

Contact: Douglas Keddy
dkeddy@uwo.ca
519-661-2111 x87485
University of Western Ontario
Source:Eurekalert

Related biology news :

1. Donation for new Center for Pharmaceutical Nanotechnology and Nanotoxicology
2. Nanotechnology culture war possible, says Yale study
3. Bangladesh Voter Registration Project Now Using MegaMatcher Biometric Technology to Detect and Prevent Duplicate Registrations
4. InvoTech Selects M2SYS Technology for Leading-Edge Fingerprint Software Solution
5. Fish technology draws renewable energy from slow water currents
6. Genetic Engineering & Biotechnology News reports on the trend toward predictive toxicogenomics
7. New filtering technology has environmental, industrial applications
8. NIST, NCI bring web 2.0 tools to nanotechnology standards effort
9. e-Smart Technologies to Introduce Next Generation I AM Smart Card Technology at Cartes 2008 in Paris
10. Cost-effective farm waste-to-energy technology focus of research
11. Nanotechnology boosts war on superbugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... India , December 7, 2016 According to a ... Machine Learning), Software Tool (Facial Expression, Voice Recognition), Service, Application Area, End User, ... is estimated to grow from USD 6.72 Billion in 2016 to USD 36.07 ... Continue Reading ... ...
(Date:12/7/2016)...   Veridium , a leader in biometrics-based ... CEO James Stickland . Stickland, a seasoned ... has served in senior executive roles for HSBC, ... expanding a pipeline of venture capital and accelerating ... served as managing director of U.K.-based fintech firm ...
(Date:12/6/2016)... Securus Technologies, a leading provider of ... safety, investigation, corrections and monitoring, and the Prison ... (5) year funding commitment by Securus to PEP ... and reentry support to more inmates and their ... the Prison Entrepreneurship Program (PEP) is an independent ...
Breaking Biology News(10 mins):
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... ... and paralysis, today announced that it has submitted a 510(k) to the FDA, ... that utilize MYOLYN’s patent-pending functional electrical stimulation (FES) technology. , The submission ...
(Date:1/18/2017)... OF PRUSSIA, PA (PRWEB) , ... January 18, ... ... disrupt clinical operations again at the CHI SCOPE Summit for Clinical Ops Executives ... AstraZeneca in engaging panel discussions to examine vital clinical research issues such as ...
(Date:1/18/2017)... Francisco, CA (PRWEB) , ... January 18, 2017 ... ... to report the publishing of the latest paper by its Science Editor, Dr. ... Microbiology (Nederlands Tijdschrift voor Medische Microbiologie). Dr. Bik joined uBiome in October 2016 ...
(Date:1/18/2017)... 2017 Shareholder rights law firm Johnson & ... board members of CoLucid Pharmaceuticals, Inc. (NASDAQ: ... the proposed sale of the Company to Eli Lilly ... small molecules for the acute treatment of migraines. ... signed a definitive merger agreement with Eli Lilly. Under ...
Breaking Biology Technology: